Tevard Biosciences Pursues Gene Therapy to Treat Dravet Syndrome and Possibly DMD
Tevard Biosciences aims to use transfer RNA (tRNA) to modulate RNA function to treat Dravet syndrome and other rare diseases.
DS Features
Ovid and Takeda Bank On Soticlestat as a Novel Therapy for Dravet, Lennox-Gastaut
Ovid Therapeutics and Takeda Pharmaceuticals are pursuing soticlestat as a potential therapy to reduce seizures in people with Dravet or Lennox-Gastaut syndrome.
California Epilepsy Expert Argues for More Liberal Federal Cannabis Laws
California pediatrician and neurological expert Bonni Goldstein, MD, has become a fierce advocate for using medical cannabis to treat rare epilepsies.
A Variety of SCN1A-Targeted Therapies Show Promise in Treating Dravet Syndrome
Gene therapy approaches that target the SCN1A gene are being developed to correct the genetic defect underlying Dravet syndrome.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in DS Features
Loading... 
Loading...